Sign in Subscribe

colon

A collection of 4 issues

AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA AZUR-4 Phase II trial tests neoadjuvant dostarlimab plus CAPEOX in MSS stage III colon cancer This randomized Phase II study compares neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon

Dual immunotherapy shows promise in mismatch repair proficient colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA Dual immunotherapy shows promise in mismatch repair proficient colon cancer The phase 2 NEST trial tested neoadjuvant botensilimab plus balstilimab in patients with resectable colon cancer. The study examined safety, feasibility, and pathologic response before surgical resection. (Clinical Cancer Research) This content

Phase 2 trial tests dostarlimab plus chemotherapy before surgery in stage III colon cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 trial tests dostarlimab plus chemotherapy before surgery in stage III colon cancer The AZUR-4 trial is comparing neoadjuvant dostarlimab plus CAPEOX versus CAPEOX alone in previously untreated T4N0 or stage III mismatch repair proficient/microsatellite stable resectable colon cancer. (Clinical

MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient

Skip to content The CRC Digest MSI-H tumor responds to immunotherapy while MSI-stable tumor does not in same patient Exceptional case of synchronous colon cancers with different MMR status provides direct in vivo evidence of ICI responsiveness differences. (Japanese Journal of Clinical Oncology) This content is informational only and does